December 07, 2022 21:44 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Need PM and centre's blessing': Arvind Kejriwal after winning MCD polls | India could soon experience heat waves that could break human survivability limit: World Bank report | Arvind Kejriwal reacts to exit polls claiming BJP sweeping Gujarat | PM Modi chairs all-party meet over India's G20 presidency | 'Cocaine started coming into India': Nirmala Sitharaman warns officers, asks to up vigil
Covaxin's approval premature, dangerous: Shashi Tharoor Coronavirus Vaccine

Covaxin's approval premature, dangerous: Shashi Tharoor

India Blooms News Service | @indiablooms | 03 Jan 2021, 03:04 pm

New Delhi/UNI: Congress leader and Thiruvananthapuram MP Shashi Tharoor on Sunday expressed apprehensions over the DCGI's nod for the emergency use of Bharat Biotech's COVID-19 vaccine 'Covaxin'.

In a tweet,  Tharoor said that the Covaxin has not completed its phase 3 trials.

"Approval was premature and could be dangerous. Dr Harsh Vardhan should please clarify," the parliamentarian averred.

Notably, the drug regulator's Subject Expert Committee (SEC) had on January 1 recommended the emergency use authorization to Serum Institute of India's Covishield and on January 2 recommended approval for both Bharat Biotech's Covaxin. The Drugs Controller General of India cleared both the vaccines for emergency approval today.

He further said that the use of Covaxin should be avoided till trials are completely over.

"India can start with the AstraZeneca vaccine in the meantime," he added.

The final decision to recommend Bharat Biotech's Covaxin after it presented updated data and justification and request for consideration of their proposal amid cases of mutant Coronavirus strain.

However, the SEC stated that the firm should continue with phase 3 clinical trial and submit the results emerging from the trial whenever available, sources said, reported the India Express.